Drug discovery dilemma and Cura quartet collaboration.
Many parties contribute to discovery of new drugs - academic researchers, industry scientists, government agencies, and disease foundation helping to corral the resources necessary to sustain research efforts - but it has never been more apparent until now that these parties must work together to accomplish the shared goal of improving health. At a recent conference at the Georgetown University Medical Center, a group of prominent scientists from the academic, industry, government and disease advocacy communities came together to discuss new paths forward for stronger inter-institutional collaboration to establish a framework for translating new discoveries into drugs, improving proof of concept (PoC) studies, and reducing attrition at the clinical stage of drug development.
Shah
Salim
S
Office of Planning and Enterprise Development, Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington DC 20057, USA. ss234@georgetown.edu
Federoff
Howard J
HJ
D000818:Animals; D015415:Biomarkers; D002986:Clinical Trials as Topic; D003299:Cooperative Behavior; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry; D005582:Foundations; D006076:Government; D006801:Humans; D015203:Reproducibility of Results; D012106:Research; D012107:Research Design; D012109:Research Support as Topic; D014495:Universities
D015415:Biomarkers